Cite
APA Citation
Mayerhoefer, M. E., Karanikas, G., Kletter, K., Kiesewetter, B., Weber, M., Rausch, I., Pones, M., Simonitsch-Klupp, I., Müllauer, L., Dolak, W., Lukas, J., & Raderer, M. (2016). can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?. Clinical nuclear medicine, 41, . http://access.bl.uk/ark:/81055/vdc_100041947016.0x000033